{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:41:30Z","timestamp":1787240490268,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["T32AR048522"],"award-info":[{"award-number":["T32AR048522"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["T32AR048522"],"award-info":[{"award-number":["T32AR048522"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K23AR075898"],"award-info":[{"award-number":["K23AR075898"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K08AR077732"],"award-info":[{"award-number":["K08AR077732"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K23AR073927"],"award-info":[{"award-number":["K23AR073927"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI180356"],"award-info":[{"award-number":["K23AI180356"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ira T. Discovery Fund; Buck Discovery Fund; Jerome L. Greene Foundation"},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["2T32AG058527-06A1"],"award-info":[{"award-number":["2T32AG058527-06A1"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Peter Frampton Myositis Research Fund"},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["1S10OD025226-01"],"award-info":[{"award-number":["1S10OD025226-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ira T. Discovery Fund,"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This single-arm, open-label phase 1 trial evaluated the PPAR\u03b3 agonist pioglitazone in patients with inclusion body myositis (IBM). After a 16-week observation (lead-in) period, participants received pioglitazone 45\u2009mg daily for 32 weeks. The primary outcome was the change in PPARGC1A expression and related metabolic pathways in muscle after 16 weeks of treatment compared with the lead-in period. Of the 16 enrolled participants, 13 initiated pioglitazone and completed at least one on-treatment assessment; the trial was terminated early due to the COVID-19 pandemic. At baseline, muscle metabolomics revealed broad metabolic abnormalities compared with controls. Pioglitazone reversed elements of this signature, increasing PPARGC1A expression (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.099) and modulating downstream pathways in muscle, including enhanced oxidative phosphorylation. Clinical outcomes were unchanged overall, but a subset with favorable metabolic responses showed slower decline in the IBM-Functional Rating Score (IBM-FRS) and Modified Timed Up and Go (m-TUG). Reported adverse effects included myalgia and heart failure exacerbation. As a phase 1 trial with a limited cohort, these findings provide preliminary evidence that pioglitazone modulates muscle metabolism and warrants further investigation in IBM. This study was supported by the Ira T. Discovery Fund and the Peter and Carmen Lucia Buck Foundation Myositis Discovery Fund. Clinical Trials Registration: NCT03440034.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-70262-0","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T03:34:49Z","timestamp":1773545689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Modifying muscle metabolic dysregulation in inclusion body myositis with pioglitazone: a single-arm trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9912-2435","authenticated-orcid":false,"given":"Brittany L.","family":"Adler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5417-4052","authenticated-orcid":false,"given":"Michael R.","family":"Bene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cissy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Say","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Khare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Mecoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Tiniakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie J.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1119-0279","authenticated-orcid":false,"given":"Erika","family":"Darrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Pagkatipunan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Mears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary J.","family":"Vernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7150-7306","authenticated-orcid":false,"given":"Lisa","family":"Christopher-Stine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8030-9504","authenticated-orcid":false,"given":"Jemima","family":"Albayda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"key":"70262_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ageing\/afj014","volume":"35","author":"SK Munshi","year":"2006","unstructured":"Munshi, S. K. et al. Inclusion body myositis: an underdiagnosed myopathy of older people. Age Ageing 35, 91\u201394 (2006).","journal-title":"Age Ageing"},{"key":"70262_CR2","doi-asserted-by":"publisher","first-page":"e2653","DOI":"10.1212\/WNL.0000000000012004","volume":"96","author":"S Shelly","year":"2021","unstructured":"Shelly, S. et al. Epidemiology and Natural History of Inclusion Body Myositis: A 40-Year Population-Based Study. Neurology 96, e2653\u2013e2661 (2021).","journal-title":"Neurology"},{"key":"70262_CR3","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/BOR.0000000000000752","volume":"32","author":"SA Greenberg","year":"2020","unstructured":"Greenberg, S. A. Pathogenesis of inclusion body myositis. Curr. Opin. Rheumatol. 32, 542\u2013547 (2020).","journal-title":"Curr. Opin. Rheumatol."},{"key":"70262_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40674-020-00169-4","volume":"7","author":"AM Snedden","year":"2021","unstructured":"Snedden, A. M., Lilleker, J. B. & Chinoy, H. In Pursuit of an Effective Treatment: the Past, Present and Future of Clinical Trials in Inclusion Body Myositis. Curr. Treat. Options Rheum. 7, 63\u201381 (2021).","journal-title":"Curr. Treat. Options Rheum."},{"key":"70262_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.nmd.2014.12.010","volume":"25","author":"U Lindgren","year":"2015","unstructured":"Lindgren, U. et al. Mitochondrial pathology in inclusion body myositis. Neuromuscul. Disord. 25, 281\u2013288 (2015).","journal-title":"Neuromuscul. Disord."},{"key":"70262_CR6","doi-asserted-by":"publisher","unstructured":"Hedberg-Oldfors, C. et al. Mitochondrial DNA variants in inclusion body myositis characterized by deep sequencing. Brain Pathol. https:\/\/doi.org\/10.1111\/bpa.12931 (2020).","DOI":"10.1111\/bpa.12931"},{"key":"70262_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/nan.12149","volume":"41","author":"KA Rygiel","year":"2015","unstructured":"Rygiel, K. A. et al. Mitochondrial and inflammatory changes in sporadic inclusion body myositis: mitochondrial pathology of sIBM. Neuropathol. Appl. Neurobiol. 41, 288\u2013303 (2015).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"70262_CR8","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/art.39624","volume":"68","author":"LA Munters","year":"2016","unstructured":"Munters, L. A. et al. Endurance exercise improves molecular pathways of aerobic metabolism in patients with myositis. Arthritis Rheumatol. 68, 1738\u20131750 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"70262_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/CND.0b013e3181a23c86","volume":"10","author":"LG Johnson","year":"2009","unstructured":"Johnson, L. G. et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J. Clin. Neuromuscul. Dis. 10, 178\u2013184 (2009).","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"70262_CR10","doi-asserted-by":"publisher","unstructured":"Little, J. P., Safdar, A., Cermak, N., Tarnopolsky, M. A. & Gibala, M. J. Acute endurance exercise increases the nuclear abundance of PGC-1\u03b1 in trained human skeletal muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol. https:\/\/doi.org\/10.1152\/ajpregu.00409.2009 (2010).","DOI":"10.1152\/ajpregu.00409.2009"},{"key":"70262_CR11","doi-asserted-by":"publisher","unstructured":"Gibala, M. J. et al. Brief intense interval exercise activates AMPK and p38 MAPK signaling and increases the expression of PGC-1\u03b1 in human skeletal muscle. J. Appl. Physiol. https:\/\/doi.org\/10.1152\/japplphysiol.90880.2008 (2009).","DOI":"10.1152\/japplphysiol.90880.2008"},{"key":"70262_CR12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000494723","volume":"65","author":"J-H Koo","year":"2019","unstructured":"Koo, J.-H., Kang, E.-B. & Cho, J.-Y. Resistance exercise improves mitochondrial quality control in a rat model of sporadic inclusion body myositis. Gerontology 65, 240\u2013252 (2019).","journal-title":"Gerontology"},{"key":"70262_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00125-008-1256-9","volume":"52","author":"DK Coletta","year":"2009","unstructured":"Coletta, D. K. et al. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia 52, 723\u2013732 (2009).","journal-title":"Diabetologia"},{"key":"70262_CR14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ejphar.2014.06.008","volume":"740","author":"S Takada","year":"2014","unstructured":"Takada, S. et al. Pioglitazone ameliorates the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice. Eur. J. Pharm. 740, 690\u2013696 (2014).","journal-title":"Eur. J. Pharm."},{"key":"70262_CR15","doi-asserted-by":"publisher","first-page":"22464","DOI":"10.1074\/jbc.M800842200","volume":"283","author":"I Pagel-Langenickel","year":"2008","unstructured":"Pagel-Langenickel, I. et al. PGC-1\u03b1 integrates insulin signaling, mitochondrial regulation, and bioenergetic function in skeletal muscle. J. Biol. Chem. 283, 22464\u201322472 (2008).","journal-title":"J. Biol. Chem."},{"key":"70262_CR16","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.2337\/diabetes.54.5.1392","volume":"54","author":"I Bogacka","year":"2005","unstructured":"Bogacka, I., Xie, H., Bray, G. A. & Smith, S. R. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54, 1392\u20131399 (2005).","journal-title":"Diabetes"},{"key":"70262_CR17","doi-asserted-by":"publisher","first-page":"e2466","DOI":"10.1371\/journal.pone.0002466","volume":"3","author":"V Skov","year":"2008","unstructured":"Skov, V. et al. Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome. PLoS ONE 3, e2466 (2008).","journal-title":"PLoS ONE"},{"key":"70262_CR18","doi-asserted-by":"crossref","unstructured":"H., D. V., Db, A., Bc, R. & Jb, F. The intersection of purine and mitochondrial metabolism in cancer. Cells 10, 2063 (2021).","DOI":"10.3390\/cells10102603"},{"key":"70262_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ab.2013.01.035","volume":"436","author":"B Thomas","year":"2013","unstructured":"Thomas, B. et al. A novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease. Anal. Biochem. 436, 112\u2013120 (2013).","journal-title":"Anal. Biochem."},{"key":"70262_CR20","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1111\/j.1538-7836.2007.02540.x","volume":"5","author":"L Dou","year":"2007","unstructured":"Dou, L. et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J. Thromb. Haemost. 5, 1302\u20131308 (2007).","journal-title":"J. Thromb. Haemost."},{"key":"70262_CR21","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/mus.26875","volume":"61","author":"KE Leeuwenberg","year":"2020","unstructured":"Leeuwenberg, K. E. et al. Ultrasound can differentiate inclusion body myositis from disease mimics. Muscle Nerve 61, 783 (2020).","journal-title":"Muscle Nerve"},{"key":"70262_CR22","first-page":"996","volume":"36","author":"J Albayda","year":"2018","unstructured":"Albayda, J. et al. Pattern of muscle involvement in inclusion body myositis: a sonographic study. Clin. Exp. Rheumatol. 36, 996\u20131002 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"key":"70262_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08603-9","volume":"7","author":"PD Hamann","year":"2017","unstructured":"Hamann, P. D. et al. Transcriptional profiling identifies differential expression of long non-coding RNAs in Jo-1 associated and inclusion body myositis. Sci. Rep. 7, 8024 (2017).","journal-title":"Sci. Rep."},{"key":"70262_CR24","doi-asserted-by":"publisher","unstructured":"Shah, P. & Mudaliar, S. Pioglitazone: side effect and safety profile. Expert Opin. Drug Saf. https:\/\/doi.org\/10.1517\/14740331003623218 (2010).","DOI":"10.1517\/14740331003623218"},{"key":"70262_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/s-2000-8529","volume":"108","author":"G Belcher","year":"2000","unstructured":"Belcher, G. & Matthews, D. R. Safety and tolerability of pioglitazone. Exp. Clin. Endocrinol. Diab. 108, 267\u2013273 (2000).","journal-title":"Exp. Clin. Endocrinol. Diab."},{"key":"70262_CR26","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/acn3.51657","volume":"9","author":"A Murakami","year":"2022","unstructured":"Murakami, A. et al. Metabolome and transcriptome analysis on muscle of sporadic inclusion body myositis. Ann. Clin. Transl. Neurol. 9, 1602\u20131615 (2022).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"70262_CR27","doi-asserted-by":"publisher","first-page":"102838","DOI":"10.1016\/j.jbc.2022.102838","volume":"299","author":"PK Arnold","year":"2023","unstructured":"Arnold, P. K. & Finley, L. W. S. Regulation and function of the mammalian tricarboxylic acid cycle. J. Biol. Chem. 299, 102838 (2023).","journal-title":"J. Biol. Chem."},{"key":"70262_CR28","doi-asserted-by":"crossref","unstructured":"Gf, Z. et al. Reductive TCA cycle metabolism fuels glutamine- and glucose-stimulated insulin secretion. Cell metab. 33, 804\u2013817 (2021).","DOI":"10.1016\/j.cmet.2020.11.020"},{"key":"70262_CR29","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.cmet.2018.03.002","volume":"27","author":"Q Chen","year":"2018","unstructured":"Chen, Q. et al. Rewiring of glutamine metabolism is a bioenergetic adaptation of human cells with mitochondrial DNA mutations. Cell Metab. 27, 1007\u20131025.e5 (2018).","journal-title":"Cell Metab."},{"key":"70262_CR30","doi-asserted-by":"crossref","unstructured":"A, C. & E, D. Thiazolidinediones and inflammation. Lupus 14, 794\u2013797 (2005).","DOI":"10.1191\/0961203305lu2223oa"},{"key":"70262_CR31","doi-asserted-by":"crossref","unstructured":"Bajaj, M. et al. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 95, 1916\u201323 (2010).","DOI":"10.1210\/jc.2009-0911"},{"key":"70262_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/jdi.12606","volume":"8","author":"T Yokota","year":"2017","unstructured":"Yokota, T. et al. Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome. J. Diab. Investig. 8, 535\u2013541 (2017).","journal-title":"J. Diab. Investig."},{"key":"70262_CR33","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","volume":"23","author":"MR Rose","year":"2013","unstructured":"Rose, M. R. 188th ENMC international workshop: inclusion body myositis, 2\u20134 December 2011, Naarden, The Netherlands. Neuromuscul. Disord. 23, 1044\u20131055 (2013).","journal-title":"Neuromuscul. Disord."},{"key":"70262_CR34","unstructured":"Kendall, F. P., McCreary, E. K., Provance, P. G., Rodgers, M. M. & Romani, W. A. Muscles Testing and Function with Posture and Pain. (Lippincott Williams & Wilkins, 2005)."},{"key":"70262_CR35","doi-asserted-by":"crossref","unstructured":"Hc, R. et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing 40, 423\u2013429 (2011).","DOI":"10.1093\/ageing\/afr051"},{"key":"70262_CR36","unstructured":"Podsiadlo, D. & Richardson, S. The Timed \u201cUp & Go\u201d: a test of basic functional mobility for frail elderly persons. J. Neuroeng. Rehabil. 11, 83 (2014)."},{"key":"70262_CR37","doi-asserted-by":"crossref","unstructured":"L, E. The Six-Minute Walk Test. Respir. Care 48, 783\u20135 (2003).","DOI":"10.4187\/respcare.03480783"},{"key":"70262_CR38","doi-asserted-by":"crossref","unstructured":"Jackson, C. E., Barohn, R. J., Gronseth, G., Pandya, S. & Herbelin, L. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 37, 473\u2013476 (2008).","DOI":"10.1002\/mus.20958"},{"key":"70262_CR39","doi-asserted-by":"crossref","unstructured":"Alexanderson, H. et al. Functional index-2: validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum. 55, 114\u2013122 (2006).","DOI":"10.1002\/art.21715"},{"key":"70262_CR40","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S0022-3476(82)80286-2","volume":"101","author":"JZ Heckmatt","year":"1982","unstructured":"Heckmatt, J. Z., Leeman, S. & Dubowitz, V. Ultrasound imaging in the diagnosis of muscle disease. J. Pediatr. 101, 656\u2013660 (1982).","journal-title":"J. Pediatr."},{"key":"70262_CR41","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ana.1023","volume":"49","author":"KR Wagner","year":"2001","unstructured":"Wagner, K. R. et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann. Neurol. 49, 706\u2013711 (2001).","journal-title":"Ann. Neurol."},{"key":"70262_CR42","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1093\/gerona\/glab315","volume":"77","author":"R Westbrook","year":"2022","unstructured":"Westbrook, R. et al. Metabolomics-based identification of metabolic dysfunction in frailty. J. Gerontol. A Biol. Sci. Med. Sci. 77, 2367\u20132372 (2022).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70262-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70262-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70262-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:51:14Z","timestamp":1779378674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70262-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70262"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70262-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.D. is currently an employee of AstraZeneca. A.L. is the founder and CEO of Gigantest. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3995"}}